Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: A report of two cases

Human Pathology

Volumn 27, Issue 12, 1996, Pages 1377-1381

  Mai, Kien T ^a   Commons, A Susan ^b   Perkins, D Garth ^b   Yazdi, Hossein M ^b   Collins, John P ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

hormone therapy; neuroendocrine; prostate; prostate specific antigen; prostatic adenocarcinoma

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOPSY; CASE REPORT; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PROSTATE ADENOCARCINOMA; TRANSURETHRAL RESECTION; TUMOR DIAGNOSIS;

EID: 0029807869     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90354-8     Document Type: Article

References (23)

1. Narayan P: Neoplasms of the prostate gland, in Tanagho EA, McAninch JW (eds): Smith's General Urology. Norwalk, CT, Appleton & Lange, 1995, pp 392-433
2. May EE, Perentes E: Anti-Leu 7 immunoreactivity with human tumours: Its value in the diagnosis of prostatic adenocarcinoma. Histopathology 11:295-304, 1987
3. Catalona WJ, Ritchie JP, Ahman FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Result of a multicenter clinical trial of 6,630 men (see comments). J Urol 151:1283-1290, 1994
4. Goldrath DE, Messing EM: Prostate specific antigen: Not detectable despite tumour progression after radical prostatectomy. J Urol 142:1082-1084, 1980
5. Takayama TK, Krieger JN, True LD, et al: Recurrent prostate cancer despite undetectable prostate specific antigen. J Urol 148:1541-1542, 1992
6. Fair WR, Aprikian A, Sogani P, et al: The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 71:1031-1038, 1993
7. Leibman BD, Dillioglugil O, Wheeler TM, et al: Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer 76:2530-2534, 1995
8. Keillor JS, Aterman K: The response of poorly differentiated prostatic tumours to staining for prostate specific antigen and prostatic acid phosphatase: A comparative study. J Urol 137:894-896, 1987
9. Tetu B, Srigley JR, Boivin JC, et al: Effect of combination endocrine therapy (LHRH Agonist and Flutamide) on normal prostate and prostatic adenocarcinoma. Am J Surg Pathol 15:111-120, 1991
10. Brawer MK, Nagle RB, Pitts W, et al: Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates. Cancer 63:454-460, 1989
11. Grob BM, Schellhammer PF, Brassil DN, et al: Changes in immunohis-tochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer. Urology 44:525-529, 1994
12. Vernon SE, Williams WD: Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry. J Urol 130:95-98, 1983
13. Grignon D, Troster M: Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy. Prostate 7:195-202, 1985
14. Van de Voorde WM, Elgamal AA, Van Poppel HP, et al: Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer 74:3164-3175, 1994
15. Mai KT, Gerridzen RG: Sarcomatous transformation of a prostatic adenocarcinoma after radio- and chemotherapy. Can J Urol 1:78-82, 1994
16. Ro JY, Tetu B, Ayala G, et al: Small cell carcinoma of the prostate. Cancer 59:977-982, 1987
17. Papadimitriou JC, Weihing RR, Choi C, et al: Prostatic marker-negative amphicrine carcinoma of the prostate. Ultrastructural Pathol 18:357-363, 1994
18. Svanholm H: Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase. Acta Pathol Microbiol Immunol Scand Sect A 94:7-12, 1986
19. Cohen JR, Haffejee Z, Steele GM, et al: Advanced prostatic cancer with normal serum prostatic-specific antigen values. Arch Pathol Lab Med 118:1123-1126, 1994
20. Aprikian AG, Cordon-Cardo C, Fair R, et al: Characterization of neuro-endocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71:3952-3965, 1993
21. Bonkhoff H, Stein U, Remberger K: Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplasia, and neoplastic human prostate. Virchows Arch [A] Pathol Anat Histopathol 423:291-294, 1993
22. Krijnen JL, Jansen PJ, Ruizeveld de Winter JA, et al: Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 100:393-398, 1993
23. Leong ASY, Gilham P, Milios J: Cytokeratin and vimentin intermediate filament proteins in benign and neoplastic epithelium. Histopathology 13:435-442, 1988